Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cognition Therapeutics, Inc.

< Previous 1 2 Next >
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.